Trending...
- Rap Artist AVI$U Speaks Out: Slick Rick Accused of Stealing Album Title and Concept from Rising Star
- Integris Composites Joins Paris Air Show at USA Pavilion
- Chris The Wiz Unleashes Haunting New Single "Ghosts" — Cold, Raw, Unforgettable
JUPITER, Fla. - eMusicWire -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum are among the first physicians in the country to administer the newly FDA-approved drug Kisunla to patients. This groundbreaking development marks a significant milestone in neurological care, offering new hope to patients battling a range of neurological conditions.
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
More on eMusic Wire
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
More on eMusic Wire
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
More on eMusic Wire
- Dr. Jacqueline West Honored as Best Dentist in JAX by Folio Weekly
- Exciting News: Pivotal Health Solutions Acquires Revolutionary Portable Parallel Bars
- Miboxer Achieved New Goal in GILE 2025
- Jeopardy!'s Ken Jennings Headlines National Mensa Event
- Mensa Foundation Prize Awarded to Neuroscientist-Pianist
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
More on eMusic Wire
- New book, "High-Tech Heroes," redefines billionaire as someone who improves a billion lives
- Durex Products Wire Cloth Screen Media: Engineered for Maximum Performance and Durability
- OPRAH.COM Featured Award-Winning Novel AS FAR AS YOU GO BEFORE YOU HAVE TO COME BACK now Available as Audiobook
- How Kallie Boxell Helps Texas Companies Solve the Talent Equation
- KeysCaribbean Vacation Home Rentals Offers Last-Minute Booking Discount of 15 Percent
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Source: First Choice Neurology
0 Comments
Latest on eMusic Wire
- Initial Order Received from Vietnamese Maritime Security and Defense Services for Advanced Video Compression Solution: RMX; Stock Symbol: RMXI
- Why PMT's Closure Signals a New Era for Musicians
- Keebos Launches New Universal Pearl Strap That Attaches to Any Phone Case
- Nola Blue Records signs Mud Morganfield
- Work 365 Launches Certified Provider Integration (CPI) Program to Help Distributors and CSPs Navigate Microsoft's Evolving Ecosystem
- Five Aster Awards! Fusion Marketing Group Brings Home Big Wins in 2025!
- Nobody May Come A Documentary on Valerie Sassyfras' Life Premiers July 3 at The Broadside Theatre
- AI changes cryptocurrency market trading, TWL Miner launches new 1-day contract, giving away over $1 million
- A Global First: NaturismRE™ Launches the Global Urgency Index
- 14th CryptoSuper500 Report Releases: Bitcoin's Evolution into a Global Supercomputer
- Ross Toohey named Managing Director in Chesterfield, Missouri
- High Profile Gateway Race Events With Strong Brand Exposure Plus Sponsorship in Female Motorsports; $100 Million Financing Unlocked: Lottery.com
- ASI Accelerates iMIS® Innovation by Acquiring CSI's Product Suite and Expert Team
- Texas Summer Music & Arts Fest
- Season Tickets for the 2025-26 Scottsdale Philharmonic Season Now Available
- PUSHERMAN- – Best Feature Documentary Official Winner at NYC and London Festivals
- Female Motorsports Sponsorship & Expansion; Acquisition Agreement of UAE-Based Sports Incubator by Online Lottery & Sports Game Provider: Lottery.com
- Global Court Momentum Builds Against Forced Psychiatry; CCHR Urges U.S. Reform
- Integris Composites Joins Paris Air Show at USA Pavilion
- Cheryl Hines' Trailer PROWLING to Sardinia